

Tomasz Burzykowski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8798242/publications.pdf>

Version: 2024-02-01

185
papers

8,566
citations

66315

42
h-index

49868

87
g-index

193
all docs

193
docs citations

193
times ranked

11138
citing authors

#	ARTICLE	IF	CITATIONS
1	Operational characteristics of generalized pairwise comparisons for hierarchically ordered endpoints. <i>Pharmaceutical Statistics</i> , 2022, 21, 122-132.	0.7	4
2	Semi-parametric accelerated failure-time model: A useful alternative to the proportional hazards model in cancer clinical trials. <i>Pharmaceutical Statistics</i> , 2022, 21, 292-308.	0.7	2
3	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. <i>Journal of the National Cancer Institute</i> , 2022, 114, 819-828.	3.0	2
4	Surrogacy Beyond Prognosis: The Importance of "Trial-Level" Surrogacy. <i>Oncologist</i> , 2022, 27, 266-271.	1.9	29
5	Relationship Among the Foraminal Area and Demographic and Clinical Characteristics of Patients with Low Back Pain. <i>World Neurosurgery</i> , 2022, 160, e520-e528.	0.7	0
6	Predicting the number of sulfur atoms in peptides and small proteins based on the observed aggregated isotope distribution. <i>Rapid Communications in Mass Spectrometry</i> , 2021, 35, e9162.	0.7	2
7	Using an interim analysis based exclusively on an early outcome in a randomized clinical trial with a long-term clinical endpoint. <i>Pharmaceutical Statistics</i> , 2021, , .	0.7	1
8	De novo prediction of the elemental composition of peptides and proteins based on a single mass. <i>Journal of Mass Spectrometry</i> , 2020, 55, e4367.	0.7	6
9	Assessing Treatment Benefit in Immuno-oncology. <i>Statistics in Biosciences</i> , 2020, 12, 83-103.	0.6	10
10	Joint modelling of a binary and a continuous outcome measured at two cycles to determine the optimal dose. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2019, 68, 369-384.	0.5	1
11	Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoring. <i>Clinical Trials</i> , 2019, 16, 512-522.	0.7	13
12	Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1619-1627.	0.5	11
13	Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2019, 2, e1911750.	2.8	6
14	Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2019, 20, 361-370.	5.1	59
15	A Bayesian Framework Allowing Incorporation of Retrospective Information in Prospective Diagnostic Biomarker-Validation Designs. <i>Statistics in Biopharmaceutical Research</i> , 2019, 11, 311-323.	0.6	1
16	Experimental Design in Quantitative Proteomics. <i>Methods in Molecular Biology</i> , 2019, 1977, 181-197.	0.4	2
17	The retrospective study of 93 patients with transmigration of mandibular canine and a comparative analysis with a control group. <i>European Journal of Orthodontics</i> , 2019, 41, 390-396.	1.1	11
18	A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses. <i>Statistical Methods in Medical Research</i> , 2019, 28, 170-183.	0.7	12

#	ARTICLE	IF	CITATIONS
19	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. <i>Cell</i> , 2018, 173, 338-354.e15.	13.5	1,417
20	Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?. <i>Journal of the National Cancer Institute</i> , 2018, 110, 232-240.	3.0	40
21	Sequential double cross-validation for assessment of added predictive ability in high-dimensional omic applications. <i>Annals of Applied Statistics</i> , 2018, 12, .	0.5	2
22	Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results. , 2018, 6, 134.		11
23	Surrogate endpoints in advanced sarcoma trials: a meta-analysis. <i>Oncotarget</i> , 2018, 9, 34617-34627.	0.8	9
24	The search for surrogate endpoints for immunotherapy trials. <i>Annals of Translational Medicine</i> , 2018, 6, 231-231.	0.7	8
25	Use of the Beta-Binomial Model for Central Statistical Monitoring of Multicenter Clinical Trials. <i>Statistics in Biopharmaceutical Research</i> , 2017, 9, 1-11.	0.6	14
26	Precision medicine needs randomized clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 317-323.	12.5	60
27	Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question. <i>JAMA Oncology</i> , 2017, 3, 416.	3.4	4
28	Evaluation of disease-free survival (DFS) as a surrogate for overall survival (OS) in the adjuvant therapy of HER2-positive early breast cancer (EBC) calls for individual-patient data (IPD). <i>Breast</i> , 2017, 32, S26.	0.9	0
29	The Analysis of Peptide-Centric Mass-Spectrometry Data Utilizing Information About the Expected Isotope Distribution. , 2017, , 45-64.		2
30	Computational methods and challenges in hydrogen/deuterium exchange mass spectrometry. <i>Mass Spectrometry Reviews</i> , 2017, 36, 649-667.	2.8	35
31	Estimation of Diagnostic Accuracy of a Combination of Continuous Biomarkers Allowing for Conditional Dependence Between the Biomarkers and the Imperfect Reference-Test. <i>Biometrics</i> , 2017, 73, 646-655.	0.8	6
32	PLS-SEM Mediation Analysis of Gene-Expression Data for the Evaluation of a Drug Effect. <i>Lecture Notes in Computer Science</i> , 2017, , 59-69.	1.0	1
33	An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number. <i>Oncotarget</i> , 2017, 8, 17270-17278.	0.8	3
34	Tumor-size-based endpoints as surrogates for overall survival in the ARCAD Advanced Colorectal Cancer Database.. <i>Journal of Clinical Oncology</i> , 2017, 35, 766-766.	0.8	3
35	Abstract LB-004: Molecular hallmarks of cancer: Stemness. , 2017, , .		0
36	An Information-Theoretic Approach for the Evaluation of Surrogate Endpoints Based on Causal Inference. <i>Biometrics</i> , 2016, 72, 669-677.	0.8	12

#	ARTICLE	IF	CITATIONS
37	Normalisation of brain spectroscopy findings in Niemann-Pick disease type C patients treated with miglustat. <i>Journal of Neurology</i> , 2016, 263, 927-936.	1.8	20
38	Adaptive Randomization of Neratinib in Early Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1591-1594.	13.9	12
39	Development of a diagnostic test based on multiple continuous biomarkers with an imperfect reference test. <i>Statistics in Medicine</i> , 2016, 35, 595-608.	0.8	3
40	Statistical evaluation of surrogate endpoints with examples from cancer clinical trials. <i>Biometrical Journal</i> , 2016, 58, 104-132.	0.6	93
41	Neoadjuvant as Future for Drug Development in Breast Cancer Letter. <i>Clinical Cancer Research</i> , 2016, 22, 268-268.	3.2	4
42	Data-driven risk identification in phase III clinical trials using central statistical monitoring. <i>International Journal of Clinical Oncology</i> , 2016, 21, 38-45.	1.0	19
43	Statistical monitoring of data quality and consistency in the Stomach Cancer Adjuvant Multi-institutional Trial Group Trial. <i>Gastric Cancer</i> , 2016, 19, 24-30.	2.7	20
44	The Detection of Metabolite-Mediated Gene Module Co-Expression Using Multivariate Linear Models. <i>PLoS ONE</i> , 2016, 11, e0150257.	1.1	4
45	Transferring Cut-off Values between Assays for Cerebrospinal Fluid Alzheimer's Disease Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 187-199.	1.2	7
46	Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 889-899.	1.2	11
47	Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma. <i>Medicine (United States)</i> , 2015, 94, e853.	0.4	14
48	A hidden Markov-model for gene mapping based on whole-genome next generation sequencing data. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2015, 14, 21-34.	0.2	8
49	PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. <i>Clinical Cancer Research</i> , 2015, 21, 2065-2074.	3.2	59
50	A Nonhomogeneous Hidden Markov Model for Gene Mapping Based on Next-Generation Sequencing Data. <i>Journal of Computational Biology</i> , 2015, 22, 178-188.	0.8	12
51	Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. <i>Journal of Clinical Oncology</i> , 2015, 33, 1356-1363.	0.8	120
52	On the Relationship between the Causal-Inference and Meta-Analytic Paradigms for the Validation of Surrogate Endpoints. <i>Biometrics</i> , 2015, 71, 15-24.	0.8	41
53	Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1348-1355.	0.8	343
54	Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. <i>Onc Immunology</i> , 2015, 4, e1026529.	2.1	79

#	ARTICLE	IF	CITATIONS
55	Differences in the Elemental Isotope Definition May Lead to Errors in Modern Mass-Spectrometry-Based Proteomics. <i>Analytical Chemistry</i> , 2015, 87, 10747-10754.	3.2	6
56	Event-Free Survival Is a Surrogate for Overall Survival in Patients Treated for Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3744-3744.	0.6	7
57	Surrogate properties of survival endpoints in metastatic soft-tissue sarcoma: A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10547-10547.	0.8	1
58	Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2015, 33, 666-666.	0.8	1
59	CXCL5 as a potential novel prognostic factor in early stage non-small cell lung cancer: results of a study of expression levels of 23 genes. <i>Tumor Biology</i> , 2014, 35, 4619-4628.	0.8	50
60	Comparison of the Mahalanobis Distance and Pearson's χ^2 Statistic as Measures of Similarity of Isotope Patterns. <i>Journal of the American Society for Mass Spectrometry</i> , 2014, 25, 293-296.	1.2	4
61	The use of the isotopic distribution as a complementary quality metric to assess tandem mass spectra results. <i>Journal of Proteomics</i> , 2014, 98, 150-158.	1.2	8
62	Linear mixed-effects models for central statistical monitoring of multicenter clinical trials. <i>Statistics in Medicine</i> , 2014, 33, 5265-5279.	0.8	32
63	Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3538-3538.	0.8	2
64	Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy (anti-ANG/CT) in metastatic colorectal cancer (mCRC): Analysis of individual patient (pt) data from the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3578-3578.	0.8	2
65	Phase I/IIb clinical and immunologic assessment of immunotherapeutic vaccine, DPX-Survivac in women with ovarian, Fallopian tube, or peritoneal cancer (OC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5555-5555.	0.8	1
66	Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1667-1670.	3.0	78
67	Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis. <i>European Journal of Cancer</i> , 2013, 49, 1565-1577.	1.3	136
68	A Markov-chain-based regression model with random effects for the analysis of ^{18}O -labelled mass spectra. <i>Journal of Statistical Computation and Simulation</i> , 2013, 83, 145-157.	0.7	2
69	Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1600-1607.	3.0	133
70	Linear Mixed-Effects Models Using R. Springer Texts in Statistics, 2013, , .	3.8	268
71	Data Exploration. Springer Texts in Statistics, 2013, , 39-65.	3.8	0
72	Linear Models with Homogeneous Variance. Springer Texts in Statistics, 2013, , 69-88.	3.8	0

#	ARTICLE	IF	CITATIONS
73	Fitting Linear Models with Homogeneous Variance: The lm() and gls() Functions. Springer Texts in Statistics, 2013, , 89-111.	3.8	0
74	ARMD Trial: Linear Model with Heterogeneous Variance. Springer Texts in Statistics, 2013, , 159-173.	3.8	0
75	Fitting Linear Models with Heterogeneous Variance: The gls() Function. Springer Texts in Statistics, 2013, , 149-158.	3.8	1
76	Linear Models with Heterogeneous Variance. Springer Texts in Statistics, 2013, , 123-147.	3.8	0
77	Fitting Linear Models with Fixed Effects and Correlated Errors: The gls() Function. Springer Texts in Statistics, 2013, , 197-212.	3.8	0
78	Linear Model with Fixed Effects and Correlated Errors. Springer Texts in Statistics, 2013, , 177-196.	3.8	1
79	ARMD Trial: Modeling Correlated Errors for Visual Acuity. Springer Texts in Statistics, 2013, , 213-241.	3.8	0
80	Linear Mixed-Effects Model. Springer Texts in Statistics, 2013, , 245-273.	3.8	54
81	Fitting Linear Mixed-Effects Models: The lme()Function. Springer Texts in Statistics, 2013, , 275-301.	3.8	3
82	Fitting Linear Mixed-Effects Models: The lmer() Function. Springer Texts in Statistics, 2013, , 303-326.	3.8	8
83	PRT Trial: Modeling Muscle Fiber Specific-Force. Springer Texts in Statistics, 2013, , 385-430.	3.8	0
84	SII Project: Modeling Gains in Mathematics Achievement-Scores. Springer Texts in Statistics, 2013, , 431-463.	3.8	0
85	ARMD Trial: Modeling Visual Acuity. Springer Texts in Statistics, 2013, , 327-384.	3.8	0
86	FCAT Study: Modeling Attainment-Target Scores. Springer Texts in Statistics, 2013, , 465-489.	3.8	0
87	Extensions of theRTools for Linear Mixed-Effects Models. Springer Texts in Statistics, 2013, , 491-523.	3.8	0
88	BRAIN: A Universal Tool for High-Throughput Calculations of the Isotopic Distribution for Mass Spectrometry. Analytical Chemistry, 2013, 85, 1991-1994.	3.2	38
89	Markers for nutrition studies: review of criteria for the evaluation of markers. European Journal of Nutrition, 2013, 52, 1685-1699.	1.8	18
90	Evaluation of Normalization Methods to Pave the Way Towards Large-Scale LC-MS-Based Metabolomics Profiling Experiments. OMICS A Journal of Integrative Biology, 2013, 17, 473-485.	1.0	89

#	ARTICLE	IF	CITATIONS
91	Surrogate end points: when should they be used?. <i>Clinical Investigation</i> , 2013, 3, 1147-1155.	0.0	0
92	Simultaneous Mapping of Multiple Gene Loci with Pooled Segregants. <i>PLoS ONE</i> , 2013, 8, e55133.	1.1	10
93	Genomic Biomarkers for a Binary Clinical Outcome in Early Drug Development Microarray Experiments. <i>Journal of Biopharmaceutical Statistics</i> , 2012, 22, 72-92.	0.4	1
94	Reply to the Comment on:. <i>Journal of the American Society for Mass Spectrometry</i> , 2012, 23, 1828-1829.	1.2	9
95	Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 773-783.	1.9	22
96	Predicting Treatment Effect from Surrogate Endpoints and Historical Trials: An Extrapolation Involving Probabilities of a Binary Outcome or Survival to a Specific Time. <i>Biometrics</i> , 2012, 68, 248-257.	0.8	14
97	A statistical approach to central monitoring of data quality in clinical trials. <i>Clinical Trials</i> , 2012, 9, 705-713.	0.7	83
98	An Efficient Method to Calculate the Aggregated Isotopic Distribution and Exact Center-Masses. <i>Journal of the American Society for Mass Spectrometry</i> , 2012, 23, 753-763.	1.2	40
99	The isotopic distribution conundrum. <i>Mass Spectrometry Reviews</i> , 2012, 31, 96-109.	2.8	73
100	A Bayesian Model Averaging Approach to the Quantification of Overlapping Peptides in an MALDI-TOF Mass Spectrum. <i>International Journal of Proteomics</i> , 2011, 2011, 1-14.	2.0	3
101	Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. <i>Blood</i> , 2011, 117, 7007-7013.	0.6	73
102	A Bayesian Markov-Chain-Based Heteroscedastic Regression Model for the Analysis of 18O-Labeled Mass Spectra. <i>Journal of the American Society for Mass Spectrometry</i> , 2011, 22, 499-507.	1.2	2
103	The correlation structure of longitudinal measurements of vision in patients with macular degeneration. <i>Pharmaceutical Statistics</i> , 2011, 10, 115-121.	0.7	3
104	Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials. <i>Computational Statistics and Data Analysis</i> , 2011, 55, 2748-2757.	0.7	23
105	Evaluation of Laplace distribution-based ANOVA models applied to microarray data. <i>Journal of Applied Statistics</i> , 2011, 38, 937-950.	0.6	1
106	A Markov-Chain Model for the Analysis of High-Resolution Enzymatically 18O-Labeled Mass Spectra. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2011, 10, Article 1.	0.2	5
107	Progression-free survival as surrogate endpoint of overall survival in patients with advanced/recurrent gastric cancer: Individual patient data analysis on 4,102 patients from 20 randomized trials.. <i>Journal of Clinical Oncology</i> , 2011, 29, 4095-4095.	0.8	3
108	Simplified modeling strategies for surrogate validation with multivariate failure-time data. <i>Computational Statistics and Data Analysis</i> , 2010, 54, 1457-1466.	0.7	1

#	ARTICLE	IF	CITATIONS
109	Missing data: Discussion points from the PSI missing data expert group. <i>Pharmaceutical Statistics</i> , 2010, 9, 288-297.	0.7	21
110	A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials. <i>Statistical Methods in Medical Research</i> , 2010, 19, 205-236.	0.7	18
111	Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1729.	3.8	711
112	Markov-Chain-Based Heteroscedastic Regression Model for the Analysis of High-Resolution Enzymatically ¹⁸ O-Labeled Mass Spectra. <i>Journal of Proteome Research</i> , 2010, 9, 2669-2677.	1.8	14
113	Abstract P3-10-24: Fibroblast Growth Factor Receptor 1 Amplification and Overexpression in Breast Cancer Tissue Microarrays Using Chromogenic In Situ Hybridization and Immunohistochemistry. , 2010, , .		0
114	A strategy for the prior processing of high-resolution mass spectral data obtained from high-dimensional combined fractional diagonal chromatography. <i>Journal of Mass Spectrometry</i> , 2009, 44, 516-529.	0.7	10
115	A Comparison of Procedures for Controlling the False Discovery Rate in the Presence of Small Variance Genes: A Simulation Study. <i>Communications in Statistics Part B: Simulation and Computation</i> , 2009, 38, 2111-2122.	0.6	0
116	Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. <i>Lancet Oncology</i> , The, 2009, 10, 341-350.	5.1	138
117	A model-based method for the prediction of the isotopic distribution of peptides. <i>Journal of the American Society for Mass Spectrometry</i> , 2008, 19, 703-712.	1.2	44
118	Exploring and validating surrogate endpoints in colorectal cancer. <i>Lifetime Data Analysis</i> , 2008, 14, 54-64.	0.4	30
119	An Investigation on Performance of Significance Analysis of Microarray (SAM) for the Comparisons of Several Treatments with one Control in the Presence of Small Variance Genes. <i>Biometrical Journal</i> , 2008, 50, 801-823.	0.6	12
120	The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials. <i>Journal of Statistical Planning and Inference</i> , 2008, 138, 432-449.	0.4	17
121	Fitting Conditional Survival Models to Meta-Analytic Data by Using a Transformation Toward Mixed-Effects Models. <i>Biometrics</i> , 2008, 64, 834-842.	0.8	4
122	Titration of <i>Theileria parva</i> : Single stocks against combination of stocks. <i>Experimental Parasitology</i> , 2008, 118, 522-530.	0.5	1
123	Performance of Gene Selection and Classification Methods in a Microarray Setting: A Simulation Study. <i>Communications in Statistics Part B: Simulation and Computation</i> , 2008, 37, 409-424.	0.6	6
124	Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1980-1986.	0.8	189
125	Surrogate endpoints: wishful thinking or reality?. <i>Statistical Methods in Medical Research</i> , 2008, 17, 463-466.	0.7	13
126	Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1987-1992.	0.8	314

#	ARTICLE	IF	CITATIONS
127	Individual- and trial-level surrogacy in colorectal cancer. <i>Statistical Methods in Medical Research</i> , 2008, 17, 467-475.	0.7	65
128	A Cross-Validation Study to Select a Classification Procedure for Clinical Diagnosis Based on Proteomic Mass Spectrometry. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2008, 7, Article12.	0.2	9
129	Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5218-5224.	0.8	321
130	Finding Clusters of Positive and Negative Coregulated Genes in Gene Expression Data. , 2007, , .		3
131	Testing for Trends in Dose-Response Microarray Experiments: A Comparison of Several Testing Procedures, Multiplicity and Resampling-Based Inference. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2007, 6, Article26.	0.2	23
132	Using Linear Mixed Models for Normalization of cDNA Microarrays. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2007, 6, Article 19.	0.2	9
133	Are Prostate-Specific Antigen Changes Valid Surrogates for Survival in Hormone-Refractory Prostate Cancer? A Meta-Analysis Is Needed!. <i>Journal of Clinical Oncology</i> , 2007, 25, 5673-5674.	0.8	15
134	Reintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3224-3229.	0.8	121
135	Comparison of different estimation procedures for proportional hazards model with random effects. <i>Computational Statistics and Data Analysis</i> , 2007, 51, 3913-3930.	0.7	19
136	Using a Poisson approximation to predict the isotopic distribution of sulphur-containing peptides in a peptide-centric proteomic approach. <i>Rapid Communications in Mass Spectrometry</i> , 2007, 21, 3387-3391.	0.7	20
137	The Use of Background Signal in the Transformation of cDNA-Microarray Measurements. <i>Applied Bioinformatics</i> , 2006, 5, 161-172.	1.7	1
138	A Modeling Approach to the Analysis of Nerve Regenerative Experiments. <i>Journal of Biopharmaceutical Statistics</i> , 2006, 16, 843-859.	0.4	0
139	Resampling Plans for Frailty Models. <i>Communications in Statistics Part B: Simulation and Computation</i> , 2006, 35, 497-514.	0.6	9
140	Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. <i>European Journal of Cancer</i> , 2006, 42, 1344-1350.	1.3	70
141	Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. <i>Pharmaceutical Statistics</i> , 2006, 5, 173-186.	0.7	150
142	No association of leukemia inhibitory factor (LIF) DNA polymorphisms with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2006, 171, 189-192.	1.1	5
143	Vegetables Affect the Expression of Genes Involved in Anticarcinogenic Processes in the Colonic Mucosa of C57Bl/6 Female Mice. <i>Journal of Nutrition</i> , 2005, 135, 1879-1888.	1.3	16
144	The effects of foot disease on quality of life: results of the Achilles Project. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2005, 19, 191-195.	1.3	37

#	ARTICLE	IF	CITATIONS
145	Risk factors for bovine herpesvirus-1 seropositivity. <i>Preventive Veterinary Medicine</i> , 2005, 69, 285-295.	0.7	59
146	Design and Analysis of Drug Combination Experiments. <i>Biometrical Journal</i> , 2005, 47, 299-308.	0.6	68
147	A Version of the EM Algorithm for Proportional Hazard Model with Random Effects. <i>Biometrical Journal</i> , 2005, 47, 847-862.	0.6	32
148	Vegetables Affect the Expression of Genes Involved in Carcinogenic and Anticarcinogenic Processes in the Lungs of Female C57Bl/6 Mice. <i>Journal of Nutrition</i> , 2005, 135, 2546-2552.	1.3	11
149	Statistical Interaction in the Survival Analysis of Early Breast Cancer using Registry Data: Role of Breast Conserving Surgery and Radiotherapy. <i>Tumori</i> , 2005, 91, 9-14.	0.6	4
150	Is Prostate-Specific Antigen a Valid Surrogate End Point for Survival in Hormonally Treated Patients With Metastatic Prostate Cancer? Joint Research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. <i>Journal of Clinical Oncology</i> , 2005, 23, 6139-6148.	0.8	107
151	Axillary Sentinel Node and Tumour-related Factors Associated with Non-sentinel Node Involvement in Breast Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2004, 34, 519-524.	0.6	36
152	Efficacy of Oral Adjuvant Therapy After Resection of Colorectal Cancer: 5-Year Results From Three Randomized Trials. <i>Journal of Clinical Oncology</i> , 2004, 22, 484-492.	0.8	133
153	The validation of surrogate end points by using data from randomized clinical trials: a case-study in advanced colorectal cancer. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2004, 167, 103-124.	0.6	69
154	Prentice's Approach and the Meta-Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints. <i>Biometrics</i> , 2004, 60, 724-728.	0.8	49
155	Pseudo-likelihood estimation for a marginal multivariate survival model. <i>Statistics in Medicine</i> , 2004, 23, 947-963.	0.8	7
156	Choice of units of analysis and modeling strategies in multilevel hierarchical models. <i>Computational Statistics and Data Analysis</i> , 2004, 47, 537-563.	0.7	25
157	Factors associated with non-sentinel node involvement in breast cancer. <i>European Journal of Cancer, Supplement</i> , 2004, 2, 80.	2.2	0
158	A perspective on surrogate endpoints in controlled clinical trials. <i>Statistical Methods in Medical Research</i> , 2004, 13, 177-206.	0.7	49
159	Predicted and observed thyroid cancer incidence in Poland after year 1986. <i>Wiadomości Lekarskie</i> , 2004, 57, 306-10.	0.1	2
160	High prevalence of foot diseases in Europe: results of the Achilles Project. <i>Mycoses</i> , 2003, 46, 496-505.	1.8	162
161	Analysis of photon count data from single-molecule fluorescence experiments. <i>Chemical Physics</i> , 2003, 288, 291-307.	0.9	17
162	Using the Expected Survival to Explain Differences Between the Results of Randomized Trials: A Case in Advanced Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 1682-1687.	0.8	12

#	ARTICLE	IF	CITATIONS
163	Simplified hierarchical linear models for the evaluation of surrogate endpoints. <i>Journal of Statistical Computation and Simulation</i> , 2003, 73, 643-658.	0.7	40
164	Multivariate Analysis of Risk Factors for Development of Duodenal Ulcer in <i>Helicobacter pylori</i> -Infected Patients. <i>Digestion</i> , 2003, 67, 25-31.	1.2	11
165	Design-based analysis of surveys: a bovine herpesvirus 1 case study. <i>Epidemiology and Infection</i> , 2003, 131, 991-1002.	1.0	10
166	Validation of a longitudinally measured surrogate marker for a time-to-event endpoint. <i>Journal of Applied Statistics</i> , 2003, 30, 235-247.	0.6	24
167	Statistical analysis of data from single molecule experiment. , 2003, 5258, 171.		3
168	Validation of Biomarkers as Surrogates for Clinical Endpoints. <i>Drugs and the Pharmaceutical Sciences</i> , 2003, , .	0.1	7
169	Post-surgery radiation in early breast cancer: survival analysis of registry data. <i>Radiotherapy and Oncology</i> , 2002, 64, 281-290.	0.3	40
170	Statistical challenges in the evaluation of surrogate endpoints in randomized trials. <i>Contemporary Clinical Trials</i> , 2002, 23, 607-625.	2.0	108
171	Is there a minimum number of lymph nodes that should be histologically assessed for a reliable nodal staging of T3N0M0 colorectal carcinomas?. <i>Journal of Surgical Oncology</i> , 2002, 81, 63-69.	0.8	111
172	Validation of Surrogate Endpoints in Multiple Randomized Clinical Trials with Discrete Outcomes. <i>Biometrical Journal</i> , 2002, 44, 921-935.	0.6	44
173	Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis. <i>Lung Cancer</i> , 2001, 34, S59-S64.	0.9	48
174	Prognostic significance of p53 and bcl-2 abnormalities in operable nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2001, 17, 660-666.	3.1	43
175	Validation of surrogate end points in multiple randomized clinical trials with failure time end points. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2001, 50, 405-422.	0.5	163
176	Re: A Model to Select Chemotherapy Regimens for Phase III Trials for Extensive-Stage Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2001, 93, 399-400.	3.0	7
177	p53 gene mutation and protein expression in operable non-small cell lung cancer in Poland. <i>European Journal of Cancer Prevention</i> , 2000, 9, 81-88.	0.6	6
178	Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. <i>Lancet, The</i> , 2000, 356, 373-378.	6.3	395
179	Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: results of a randomized multicenter Pol-GIK trial. <i>Cardiovascular Drugs and Therapy</i> , 1999, 13, 191-200.	1.3	120
180	The effect of long-term water storage on the tensile strength of orthodontic brackets bonded with resin-reinforced glass-ionomer cements. <i>Journal of Orofacial Orthopedics</i> , 1999, 60, 361-370.	0.5	10

#	ARTICLE	IF	CITATIONS
181	Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer. Lung Cancer, 1998, 22, 191-200.	0.9	26
182	Preoperative CYFRA 21-1 level as a prognostic indicator in resected nonsmall cell lung cancer. European Respiratory Journal, 1998, 12, 1424-1428.	3.1	22
183	Preoperative CYFRA 21-1 level as a prognostic indicator in resected primary squamous cell lung cancer. British Journal of Cancer, 1996, 74, 956-960.	2.9	20
184	Applied Surrogate Endpoint Evaluation Methods with SAS and R. , 0, , .		17
185	Effect of the number of uninvolved nodes on survival in early breast cancer. Oncology Reports, 0, , .	1.2	15